Drug intelligence / Profile preview

JX2105

Development stage: Phase 1
Lead developer: Jingxin Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

JX2105 is a small molecule chemical drug in development by Zhejiang Jingxin Pharmaceutical for the treatment of neurological disorders, with its primary indication being Parkinson's disease. The drug is classified as an antiparkinsonian agent. Its mechanism of action has not been defined or disclosed publicly. As of October 2024, JX2105 is considered a new molecular entity and has reached Phase 1 clinical trials in China to evaluate its safety, tolerability, and pharmacokinetics in healthy subjects[1][2][3]. The route of administration is oral.

Beyond the preview

Go deeper on JX2105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JX2105.

Explore the full profile